-
Pharmacokinetics and short-term safety and tolerability of
etravirine in treatment-experienced HIV-1-infected
children and adolescents.
Königs C, Feiterna-Sperling C, Esposito S, et al
AIDS.
2011 Dec 7
Abstract
-
Etravirine-based highly active antiretroviral therapy in HIV-1-infected
paediatric patients.
Briz V, Palladino C, Navarro M,
et al
HIV Med. 2011 Mar 13. doi: 10.1111
Abstract
-
POSTER
Prevalence and
Predictors of RAM to ETV in Perinatally HIV-1-infected Children, 1998 to 2009
G Contreras, C Bell, G
Delbianco, et al
PDF Poster
Abstract
-
POSTER
Pharmacokinetics and Dose Selection of Etravirine in HIV-infected
Children between 6 and 17 Years,
Inclusive
C Königs, C
Feiterna-Sperling, S Esposito, et al
(16 CROI)
PDF Poster
Abstract
-
Profiling Etravirine Resistance in Ugandan Children with Extended Failure
of a NNRTI-inclusive Regimen as
First-line ART
A Kekitiinwa, D
Friedman, E Coakley, et al
(16 CROI)
Abstract
-
Bioavailability of the 100mg etravirine tablet dispersed in water and of
the 25mg pediatric tablet formulation
M. Schöller-Gyüre, T.N. Kakuda, R.M. Van Solingen-Ristea, et al
(XVII International AIDS Conference)
Abstract
-
POSTER
Pharmacokinetics of the
Next-generation NNRTI TMC125 in HIV-infected Children between 6 and
17 Years of Age
T Kakuda, C Konigs, C
Feiterna-Sperling, et al
(15th CROI)
PDF Poster
Abstract
|
New
and Noteworthy
Journal
Citations
Database
of ARV Drug Interactions